Evercore analyst Liisa Bayko upgrades $Editas Medicine (EDIT.US)$ to a buy rating, and maintains the target price at $7.
According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of 10.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The company's third-quarter outcomes were supplementary to the earlier strategic update, according to the analyst.
The primary discussion among investors regarding Editas Medicine centers on determining if the company's new strategy represents progress or a regression. However, it is believed that reni-cel for sickle cell disease and transfusion-dependent thalassemia stands as a de-risked asset with potential for monetization. This asset also provides crucial insights that could be advantageous as management deliberates future approaches for their in vivo candidate.
Editas Medicine's emphasis on in vivo HSPC editing is still viewed as a strategic and efficient allocation of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline updates anticipated in the first quarter of 2025, along with further developments on reni-cel BD activity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Liisa Bayko上調$Editas Medicine (EDIT.US)$至買入評級，維持目標價7美元。
根據TipRanks數據顯示，該分析師近一年總勝率為45.8%，總平均回報率為10.6%。
此外，綜合報道，$Editas Medicine (EDIT.US)$近期主要分析師觀點如下：
分析師稱，該公司第三季度的業績是對先前戰略更新的補充。
投資者關於Editas Medicine的主要討論集中在確定公司的新戰略是進步還是倒退。但是，據信，治療鐮狀細胞病和依賴輸血的地中海貧血的reni-cel是一種無風險資產，具有獲利潛力。該資產還提供了重要的見解，在管理層爲其體內候選人考慮未來的方法時，這些見解可能具有優勢。
Editas Medicine對體內HSPC編輯的重視仍被視爲其專業知識和資源的戰略和有效分配，以創造價值。預計將於2025年第一季度進行的體內產品線更新以及reni-cel BD活動的進一步發展，人們的期望越來越高。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
